2025 Japan Asthma Drugs Market Revenue Opportunities Report
Description
The 2025 Japan Asthma Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Asthma Drugs Market in Japan are GlaxoSmithKline (GSK), Novartis, Merck & Co., and AstraZeneca. GSK is a prominent player, highlighted by its approval of Relvar Ellipta in Japan, a once-daily inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) treatment offering 24-hour efficacy, demonstrating their commitment to treating bronchial asthma. Novartis, also significant in Japan, continues innovation in respiratory drugs focusing on effective therapies for asthma and other respiratory diseases. Merck & Co. actively contributes to asthma treatment through a range of inhaled corticosteroids and combination therapies marketed globally including Japan. AstraZeneca is another key player with a strong portfolio in respiratory therapeutics, providing combination inhalers and biologics that address severe asthma treatment needs.
These companies dominate the market by investing in innovative therapies like biologics and combination inhalers, targeting improved patient compliance and outcomes amid increasing asthma cases in Japan. Their presence is supported by collaborations, strategic R&D, and local regulatory approvals to enhance respiratory care. Japan's asthma drug market is growing rapidly with a forecast CAGR of around 5-7%, driven by increasing asthma prevalence, air pollution, and government health initiatives, which further motivates these firms to expand their respiratory portfolios and access.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Asthma Drugs Market in Japan are GlaxoSmithKline (GSK), Novartis, Merck & Co., and AstraZeneca. GSK is a prominent player, highlighted by its approval of Relvar Ellipta in Japan, a once-daily inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) treatment offering 24-hour efficacy, demonstrating their commitment to treating bronchial asthma. Novartis, also significant in Japan, continues innovation in respiratory drugs focusing on effective therapies for asthma and other respiratory diseases. Merck & Co. actively contributes to asthma treatment through a range of inhaled corticosteroids and combination therapies marketed globally including Japan. AstraZeneca is another key player with a strong portfolio in respiratory therapeutics, providing combination inhalers and biologics that address severe asthma treatment needs.
These companies dominate the market by investing in innovative therapies like biologics and combination inhalers, targeting improved patient compliance and outcomes amid increasing asthma cases in Japan. Their presence is supported by collaborations, strategic R&D, and local regulatory approvals to enhance respiratory care. Japan's asthma drug market is growing rapidly with a forecast CAGR of around 5-7%, driven by increasing asthma prevalence, air pollution, and government health initiatives, which further motivates these firms to expand their respiratory portfolios and access.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
